title: Hypothalamic-pituitary-adrenal axis function in very low birth weight infants treated with dexamethasone.
abstract: The effect of dexamethasone therapy on hypothalamic-pituitary-adrenal axis function was prospectively investigated in very low birth weight infants with bronchopulmonary dysplasia. Ten infants (mean +/- SD birth weight 825 +/- 265 g, gestation 25.8 +/- 1.9 weeks, postnatal age 33.1 +/- 17.7 days) initially received intravenous dexamethasone, 0.5 mg/kg per day for 3 days, and then were weaned over a period of 45 +/- 19.0 days to a replacement dose, followed by a metyrapone test. Morning plasma cortisol and 11-deoxycortisol levels were measured before and after an oral metyrapone dose given at midnight. Five infants (group A: birth weight 876 +/- 313 g, gestation 26.2 +/- 1.3 weeks, age of entry 31.8 +/- 22.8 days) had normal metyrapone test results, and five infants (group B: 778 +/- 234 g, 25.4 +/- 2.5 weeks, 34.4 +/- 13.4 days) had suppressed test results. Group A infants, in comparison with group B infants, had higher basal cortisol plasma levels (14.52 +/- 12.53 and 3.00 +/- 1.38 micrograms/dL, P = .047), higher postmetyrapone 11-deoxycortisol plasma levels (3.11 +/- 3.93 and 0.55 +/- 0.51 micrograms/dL, P = .028), larger differences between basal and postmetyrapone cortisol levels (7.10 +/- 4.67 and 2.12 +/- 1.31 micrograms/dL, P = .047), and larger differences between basal and postmetyrapone 11-deoxycortisol levels (2.99 +/- 3.93 and 0.29 +/- 0.25 micrograms/dL, P = .009). The hypothalamic-pituitary-adrenal axis function in group B infants eventually returned to normal when they continued to receive low-dose dexamethasone therapy after a period of 36.8 +/- 16.6 days.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division of Neonatology, Ahmanson Pediatric Center, and Cedars-Sinai Medical Center, University of California, School of Medicine, Los Angeles.
authors.forename: A L
authors.initials: AL
authors.lastname: Alkalay
authors.forename: J J
authors.initials: JJ
authors.lastname: Pomerance
authors.forename: A R
authors.initials: AR
authors.lastname: Puri
authors.forename: B J
authors.initials: BJ
authors.lastname: Lin
authors.forename: A L
authors.initials: AL
authors.lastname: Vinstein
authors.forename: N D
authors.initials: ND
authors.lastname: Neufeld
authors.forename: A H
authors.initials: AH
authors.lastname: Klein
mesh_terms: D001724:Birth Weight; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy*; D003350:Cortodoxone / Q000097:blood; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005865:Gestational Age; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000502:physiology*; D007223:Infant; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007363:Intensive Care Units, Neonatal; D008297:Male; D008797:Metyrapone; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000502:physiology*; D011446:Prospective Studies; D012119:Respiration / Q000187:drug effects
chemical_list: D003907:Dexamethasone; D003350:Cortodoxone; D006854:Hydrocortisone; D008797:Metyrapone